Skip to content

Psilocybin: all studies

Page 381 of 440: studies 3,801 to 3,810 of 4,399, newest first. Back to the psilocybin overview

Research

O uso de psilocibina é eficaz no tratamento de depressão?

Brazilian Journal of Health Review July 3, 2023 Edson Santana Gois Filho, Ana Letícia Fiscina Reis, Marco Antonio Galvão Martins de Farias et al. 1 citation

Os Inibidores da Recaptação de Serotonina (ISRS) foram descobertos na década de 1980 e, desde então, são a primeira linha para o tratamento da depressão. Nos últimos anos, pesquisas para busca de novas terapias farmacológicas vem tomando visibilidade com a descoberta dos efeitos antidepressivos dos psicodélicos. Dentro deles, destaca-se a Psilocibina, um alcalóide advindo do fungo Psilocybe...

Neuromodulatory mechanisms of N,N-dimethyltryptamine

Brain Network and Modulation July 1, 2023 Javier Hidalgo Jiménez 2 citations

N,N-dimethyltryptamine (DMT) is the simplest psychedelic tryptamine and is produced naturally by many plant and animal species, including humans. While classical psychedelics, such as lysergic acid diethylamide, or psilocybin, are gaining interest because of their therapeutic potential, DMT has yet to be fully investigated. However, preliminary clinical evidence suggests that DMT and/or...

New Pharmacologic Approaches to the Treatment of Bipolar Depression.

Drugs July 1, 2023 Kamyar Keramatian, Trisha Chakrabarty, Anais DuBow et al. 19 citations

Depression is the most commonly experienced mood state over the life span in individuals with bipolar disorder (BD) and is the primary driver of functional impairment and suicidality in BD. Despite this, there are few effective treatments for BD depression, with only a handful of atypical anti-psychotics and inconsistent evidence for traditional mood stabilizing agents. There have been few...

DOI: 10.1007/s40265-023-01872-x (opens in new tab) Full text (opens in new tab) Mental-health Psychiatric-treatment Bipolar-disorder Depression-therapy +1

Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review

Journal of Psychopharmacology July 1, 2023 Oliver Rumle Hovmand, Emil Deleuran Poulsen, Sidse Arnfred et al. 52 citations

Background: The classical psychedelics, psilocybin, peyote, ayahuasca/ N,N-dimethyltryptamine, and lysergic acid diethylamide are considered promising new treatments for psychiatric illnesses, such as depression, anxiety, addiction, and obsessive-compulsive disorders. However, their profound and characteristic subjective effects raise concern for distinctive biases in randomized clinical...

DOI: 10.1177/02698811231180276 (opens in new tab) Randomized controlled trial Clinical trial Medline Clinical psychology

Alterations to self consciousness during mindfulness meditation and Flotation REST a comparative study

June 30, 2023 Matt P D Gwyther, Jane E. Aspell 3 citations preprint

Flotation-Reduced Environmental Stimulation Therapy (REST) and mindfulness meditation (MM) are known to induce altered states of consciousness (ASC) and self-consciousness. In this study, we use a phenomenological and predictive processing (PP) framework to compare the interventions alongside the psychedelic experience. Ego-dissolution scores were greater than ego-inflation scores in both...

Classical psychedelics in psychiatry - renaissance of interest and therapeutic perspectives.

Psychiatria Polska June 30, 2023 Askaniusz Jachimowski, Krzysztof Kucia

Substances that change the states of consciousness have been used in the therapeutics of traditional cultures for hundreds of years. In the Western cultural circle, scientific curiosity and hope for a breakthrough in the treatment of various mental disorders constituted the basis of the first wave of research on humans with the use of psychedelics. After synthesizing LSD, psychedelic substances...

DOI: 10.12740/PP/150053 (opens in new tab) Full text (opens in new tab) Pharmacotheraphy Psychedelics hallucinogens Entheogens Psychoactive drugs +4

Case report: Psychedelic-induced seizures captured by intracranial electrocorticography

Frontiers in Neurology June 29, 2023 Benjamin N. Blond, Emmanuelle A. D. Schindler 11 citations

Classic psychedelics are currently re-emerging as therapeutic agents with unique clinical benefits; however, it is also important to recognize the adverse effects of this drug class. While the risk of seizures with this drug class is known, the literature is lacking in detail. We present a case of psychedelic mushroom-induced seizures in a person with refractory right temporal lobe epilepsy...

DOI: 10.3389/fneur.2023.1214969 (opens in new tab) Epilepsy Temporal lobe Adverse effect Anesthesia +2

Experts Offer Tips on Talking With Patients About Psychedelics

Psychiatric News June 28, 2023 Terri D’arrigo

Back to table of contents Previous article Next article Annual MeetingFull AccessExperts Offer Tips on Talking With Patients About PsychedelicsTerri D’ArrigoTerri D’ArrigoSearch for more papers by this authorPublished Online:28 Jun 2023https://doi.org/10.1176/appi.pn.2023.07.7.51AbstractPsychedelics differ from one another in their mechanism of action and potential effects on the body and mind....

DOI: 10.1176/appi.pn.2023.07.7.51 (opens in new tab) MDMA Counterculture Psychoanalysis Psychotherapist +2

Psychedelic Therapy Requires Enhanced Consent Discussions

Psychiatric News June 28, 2023 Nick Zagorski 1 citation

Back to table of contents Previous article Next article Annual MeetingFull AccessPsychedelic Therapy Requires Enhanced Consent DiscussionsNick ZagorskiNick ZagorskiPublished Online:28 Jun 2023https://doi.org/10.1176/appi.pn.2023.07.7.46AbstractThe presenters at an Annual Meeting session cautioned that patients pursuing psychedelic-assisted psychotherapy will benefit from physicians offering...

DOI: 10.1176/appi.pn.2023.07.7.46 (opens in new tab) Informed consent Psychotherapist Medical education Alternative medicine

Psychedelics, Meaningfulness, and the "Proper Scope" of Medicine: Continuing the Conversation.

Cambridge Quarterly of Healthcare Ethics June 27, 2023 Katherine Cheung, Kyle Patch, Brian D. Earp et al. 27 citations

Psychedelics such as psilocybin reliably produce significantly altered states of consciousness with a variety of subjectively experienced effects. These include certain changes to perception, cognition, and affect,1 which we refer to here as the acute subjective effects of psychedelics. In recent years, psychedelics such as psilocybin have also shown considerable promise as therapeutic agents...

DOI: 10.1017/s0963180123000270 (opens in new tab) Full text (opens in new tab) Psychedelics Mental health treatment Consciousness research Therapeutic medicine